MiMedx Group has been granted a patent for compositions containing amniotic fluid, a carrier, and placental tissue components. The patent also covers systems for administering these compositions. GlobalData’s report on MiMedx Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MiMedx Group, Cardiothoracic surgery instruments was a key innovation area identified from patents. MiMedx Group's grant share as of January 2024 was 59%. Grant share is based on the ratio of number of grants to total number of patents.
Kit for administering compositions of modified amniotic fluid
See Also:
A recently granted patent (Publication Number: US11865142B2) discloses a kit designed for medical applications, comprising a first composition of modified amniotic fluid that has been sterilized and desalted, a second composition with a pharmaceutically acceptable carrier, and an administration device with chambers for each composition and apertures for dispensing. The modified amniotic fluid in the kit is specified to have a salt concentration of 0.9% saline, be free of salts, cells, and cellular debris, and have a particle size less than 1 µm.
The kit offers various administration device options such as a dual-chamber sprayer or a double syringe, allowing for versatile use in treating gastrointestinal, skin, pulmonary diseases, scar formation, wound healing, and more. The method outlined in the patent involves administering the modified amniotic fluid composition to patients in need, with specific applications in treating various diseases, disorders, and post-surgical conditions. The kit's components are carefully formulated to ensure efficacy and safety in medical procedures, with the amniotic fluid's properties tailored for optimal therapeutic outcomes.
To know more about GlobalData’s detailed insights on MiMedx Group, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
